Physician profile
Bruce Wishnov
NPI 1134296395
$7,851.13
in general payments reported to CMS, 2019-2025
49 companies · $897 in 2025
The $897 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,365 · 2020: $1,342 · 2021: $1,565 · 2022: $1,116 · 2023: $817 · 2024: $750 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,464.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $891.37 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $777.36 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Galderma Laboratories, L.P. | $766.12 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $739.38 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $447.96 | 2019-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $440.58 | 2020-2025 | Zepbound, Mounjaro, Kisunla |
| Biohaven Pharmaceuticals, INC. | $340.72 | 2020-2021 | |
| Amgen INC. | $304.98 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $238.93 | 2021-2025 | Rexulti |
| Amarin Pharma, INC. | $203.28 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $201.86 | 2021-2024 | |
| Exact Sciences Corporation | $190.73 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $172.19 | 2019-2023 | Proclaim, Freestyle Libre 2 |
| Lundbeck LLC | $158.39 | 2024-2025 | Rexulti |
| Allergan, INC. | $158.07 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Wishnov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.